Prolonged exposure of colon cancer cells to 5-fluorouracil nanoparticles improves its anticancer activity
- PMID: 28344470
- PMCID: PMC5355554
- DOI: 10.1016/j.jsps.2016.05.010
Prolonged exposure of colon cancer cells to 5-fluorouracil nanoparticles improves its anticancer activity
Abstract
In this study, we aimed to improve the anticancer effect of 5-FU on human colon cancer cell lines by incorporating in poly(d,l lactic-co-glycolic acid) (PLGA) nanoparticles (NPs). The 5-FU-PLGA NPs were prepared by nanoprecipitation technique. Prepared NPs were moderately dispersed with an average diameter of 133 ± 25.19 nm. Scanning Electron Microscope (SEM) images revealed spherical structures with subtle surface irregularity. Free 5-FU dose-response curves were constructed (12.5-2000 μM) using MTT assay on HCT 116 and HT-29 cell lines for 1, 3, and 5 days. The calculated IC50 on HCT 116 were 185 μM after 1 day, 11.3 μM after 3 days, and 1.48 μM after 5 days. On HT-29, IC50 was only reached after 5 days of 5-FU treatment (11.25 μM). The HCT 116 viability following treatment with 100 μM 5-FU in free or NPs forms for 3 days was 38.8% and 18.6%, respectively. Similarly, when 250 μM was applied, HCT 116 viability was 17.03% and 14.6% after treatment with free and NPs forms of 5-FU, respectively. Moreover, HT-29 cell viability after 250 μM 5-FU treatment in free or NPs forms was 55.45% and 34.01%, respectively. We also noticed that HCT 116 cells were more sensitive to 5-FU-PLGA NPs as compared to HT-29 cells. Overall, our data indicate that 5-FU activity is time dependent and the prolonged effects created by PLGA NPs may contribute, at least in part, to the noticed enhancement of the anticancer activity of 5-FU drug.
Keywords: 5-Fluorouracil; Colon cancer; Drug delivery; Nanoparticles; PLGA.
Figures





Similar articles
-
PHBV/PLGA nanoparticles for enhanced delivery of 5-fluorouracil as promising treatment of colon cancer.Pharm Dev Technol. 2020 Feb;25(2):206-218. doi: 10.1080/10837450.2019.1684945. Epub 2019 Nov 20. Pharm Dev Technol. 2020. PMID: 31648589
-
Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.Mol Pharm. 2014 Mar 3;11(3):859-71. doi: 10.1021/mp400536z. Epub 2014 Jan 27. Mol Pharm. 2014. PMID: 24410438
-
Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil.Int J Pharm. 2017 Jan 10;516(1-2):61-70. doi: 10.1016/j.ijpharm.2016.11.012. Epub 2016 Nov 5. Int J Pharm. 2017. PMID: 27825867
-
Development of sulfadiazine-decorated PLGA nanoparticles loaded with 5-fluorouracil and cell viability.Molecules. 2015 Jan 8;20(1):879-99. doi: 10.3390/molecules20010879. Molecules. 2015. PMID: 25580685 Free PMC article.
-
EpCAM aptamer activated 5-FU-loaded PLGA nanoparticles in CRC treatment; in vitro and in vivo study.J Drug Target. 2023 Mar;31(3):296-309. doi: 10.1080/1061186X.2022.2148679. Epub 2022 Nov 27. J Drug Target. 2023. PMID: 36398476
Cited by
-
A Combination of Two Probiotics, Lactobacillus sporogenes and Clostridium butyricum, Inhibits Colon Cancer Development: An In Vitro Study.Microorganisms. 2022 Aug 23;10(9):1692. doi: 10.3390/microorganisms10091692. Microorganisms. 2022. PMID: 36144294 Free PMC article.
-
Eudragit-Coated Sporopollenin Exine Microcapsules (SEMC) of Phoenix dactylifera L. of 5-Fluorouracil for Colon-Specific Drug Delivery.Pharmaceutics. 2021 Nov 12;13(11):1921. doi: 10.3390/pharmaceutics13111921. Pharmaceutics. 2021. PMID: 34834336 Free PMC article.
-
Novel tetrahydroacridine derivatives with iodobenzoic moieties induce G0/G1 cell cycle arrest and apoptosis in A549 non-small lung cancer and HT-29 colorectal cancer cells.Mol Cell Biochem. 2019 Oct;460(1-2):123-150. doi: 10.1007/s11010-019-03576-x. Epub 2019 Jul 16. Mol Cell Biochem. 2019. PMID: 31313023 Free PMC article.
-
Mitigation of Tacrolimus-Associated Nephrotoxicity by PLGA Nanoparticulate Delivery Following Multiple Dosing to Mice while Maintaining its Immunosuppressive Activity.Sci Rep. 2020 Apr 21;10(1):6675. doi: 10.1038/s41598-020-63767-1. Sci Rep. 2020. PMID: 32317681 Free PMC article.
-
Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.Bioengineered. 2021 Dec;12(1):914-926. doi: 10.1080/21655979.2021.1896202. Bioengineered. 2021. PMID: 33678142 Free PMC article.
References
-
- Alanazi F.K., Yassin A.E., El-Badry M., Mowafy H.A., Alsarra I.A. Validated high-performance liquid chromatographic technique for determination of 5-fluorouracil: applications to stability studies and simulated colonic media. J. Chromatogr. Sci. 2009;47:558–563. - PubMed
-
- Ali I., Rahis Uddin K. Salim, Rather M.A., Wani W.A., Haque A. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets. 2011;11:135–146. - PubMed
-
- American Cancer Society . American Cancer Society; 2006. American Cancer Society’s Complete Guide to Colorectal Caner.
-
- Ashwanikumar N., Kumar N.A., Nair S.A., Kumar G.S. Dual drug delivery of 5-fluorouracil (5-FU) and methotrexate (MTX) through random copolymeric nanomicelles of PLGA and polyethylenimine demonstrating enhanced cell uptake and cytotoxicity. Colloids Surf. B: Biointerfaces. 2014;122:520–528. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources